August 20, 2013

For Immediate Release

Urologix Reports Fourth Quarter and Fiscal Year 2013 Results

Executive Summary

Fiscal year 2013 revenue totaled $16.6 million in-line with the Company’s fiscal year guidance range of $16.0 million to $17.0 million.
Fourth quarter revenue totaled $4.2 million, up 2.5% sequentially.
Completed restructuring of $7.5 million to settle outstanding liabilities related to the Prostiva license.
Introduces fiscal year 2014 total revenue guidance in the range of $15 million to $17 million.


MINNEAPOLIS — August 20, 2013 — Urologix®, Inc. (OTCQB: ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today reported financial results for its fiscal year fourth quarter and fiscal year ended June 30, 2013.


Fourth quarter fiscal year 2013 revenue totaled $4.2 million, up 2.5% sequentially from the third quarter of fiscal year 2013 and down 7.0% compared to the fourth quarter of fiscal year 2012. The sequential increase in revenue was driven by low single-digit growth in sales for both product lines, Cooled ThermoTherapy™ (CTT) and Prostiva® Radio Frequency (RF) Therapy. The year-over-year decline in revenue was driven by a low single-digit decline in sales of CTT and low double-digit declines in sales of Prostiva compared to the prior year.


“We are pleased at achieving our guidance for FY2013 and generating sequential growth in the fourth quarter. We believe these results reflect both the impact of our market development initiatives and continuing improvement in our execution.” stated Greg Fluet, Chief Executive Officer. “Our fiscal year 2014 guidance reflects both our confidence in the continued contributions to growth from execution of our sales and marketing strategy, heavily focused on patient education, as well as the recognition of the challenging healthcare environment. We enter the new fiscal year with certainty on our cash obligations reflected in the balance sheet, a strong product portfolio of leading in-office therapies for the treatment of BPH, a compelling market development program and a strong team focused on achieving improved operating performance.”


As of June 30, 2013, the Company’s cash balance was $2.3 million compared to $5.1 million as of March 31, 2013. This amount includes the impact from the $2.0 million payment to Medtronic which was made on June 28th, 2013 upon the signing of the restructuring agreement. Outside of the restructuring payment, the cash balances decreased $807,000 compared to March 31, 2013. The Company has an existing $2 million line of credit currently in place with Silicon Valley Bank, which has not yet been drawn upon.



On a full year basis, the Company’s cash balance increased $391,000 compared to June 30, 2012. The change in the cash balance over the fiscal year was impacted by the following items: (i) increased $3.8 million from a common stock offering on July 5, 2012; (ii) decreased due to the cash payment of $2.0 million paid as part of the Prostiva restructuring, though this was offset by the deferral of $2.0 million of payments due earlier in the year as part of the license agreement and for deferred inventory payments and; (iii) the receipt of $321,000 in January 2013 from the demutualization of an insurer. Net of these items, the Company utilized $3.7 million in cash during fiscal year 2013.


Gross profit for the fourth quarter of fiscal year 2013 was $1.9 million, or 45.5% of revenue, compared to $2.3 million, or 50.6% of revenue, in the fourth quarter of fiscal year 2012. Fourth quarter fiscal year 2013 cost of goods sold included an impairment charge of $274,000 related to a revaluation of intangible assets acquired with the Prostiva product line. Excluding the impairment charge, fourth quarter fiscal year 2013 non-GAAP gross margin was 52.1%. The improvement in gross margin, excluding the impairment charge, was driven primarily by a reduction in manufacturing costs and mobile expenses.


Total operating expense was $3.2 million for the fourth quarter of fiscal year 2013, down 5.3% year-over-year. Total operating expenses in the fourth quarter of fiscal year 2013 included an impairment charge of $160,000 related to a revaluation of intangible assets acquired with the Prostiva product line. Excluding this impairment charge and the gain on the change in value of acquisition consideration in both the current quarter and the fourth quarter of fiscal year 2012, operating expense declined 12.2% compared to the prior year. The decrease in total operating expense, excluding the impairment charge and gains on acquisition consideration, was driven by a decline of $399,000 in General & Administrative expense related to a shift in accreted interest expense to the interest expense line as a result of the restructuring of Medtronic liabilities in the period as well as a reduction in Sales & Marketing and Research & Development expenses of $96,000.


For the fourth quarter of fiscal year 2013, Urologix reported a net loss of $1.2 million, or $0.06 per diluted share, compared to a net loss of $1.2 million, or $0.08 per diluted share, in the fourth quarter of fiscal year 2012. The net loss in the fourth quarter of fiscal year 2013 was impacted, on a pre-tax basis, by an impairment charge of $434,000 on long-lived assets, a $206,000 gain on debt extinguishment and $65,000 paid for the medical device tax.


For the fiscal year 2013 period ended June 30, 2013, revenues totaled $16.6 million, down 2.6% compared to revenues of $17.0 million in fiscal year 2012. The year-over-year decline in revenue was driven by a mid-single-digit decline in sales of Cooled ThermoTherapy™ (CTT) products and a mid-single-digit increase in sales of Prostiva® Radio Frequency (RF) Therapy products. Prostiva growth benefitted from the inclusion of a full year of sales in fiscal year 2013 compared to approximately ten months of sales contribution following the Company’s license acquisition in fiscal year 2012.




Gross profit for fiscal year 2013 was $8.2 million, or 49.3% of sales. Excluding the impairment charge of $274,000 in the fourth quarter, fiscal year 2013 non-GAAP gross margin was 51.0%. Total operating expense of $12.1 million for fiscal year 2013 declined 3.4% year-over-year compared to $12.5 million in fiscal year 2012. Excluding the changes in the value of acquisition consideration in both periods, the gain on demutualization and impairment charges in fiscal year 2013, total operating expenses were flat year-over-year. The Company reported a net loss of $4.3 million, or $0.21 per diluted share, for fiscal year 2013, compared to a net loss of $4.7 million, or $0.32 per diluted share, in the prior fiscal year period.




The Company is introducing a fiscal year 2014 total revenue guidance range of $15 million to $17 million.


Earnings Call Information


Urologix will host a conference call with the financial community to discuss fiscal year 2013 fourth quarter results on Tuesday, August 20, 2013 at 4:00 p.m. Central Daylight Time. To listen to the call, please dial 1-877-703-6103 and enter the Participant Passcode 11902670 at least 10 minutes prior to the call. A live webcast of the call will be available through the investor relations section of the Company’s website at www.urologix.com and available for replay approximately two hours after the completion of the call.


Non-GAAP Gross Margin Percentage Reconciliation


   Three Months
June 30, 2013
   Twelve Months
June 30, 2013
Sales  $4,184,000   $16,590,000 
Cost of goods sold   2,279,000    8,407,000 
GAAP gross profit   1,905,000    8,183,000 
Impairment charge excluded from cost of goods sold   274,000    274,000 
Non-GAAP gross profit  $2,179,000   $8,457,000 
Non-GAAP gross margin percentage   52.1%    51.0% 


Notes to Reconciliation of Non-GAAP Measure to GAAP


Management believes non-GAAP financial information provides meaningful supplemental information regarding the Company’s financial performance by excluding the impairment charge to developed technology intangible asset in the fourth quarter of fiscal year 2013. Management believes this impairment charge is a non-recurring item that is not indicative of the operating results of the business. Urologix believes that this additional financial information is useful to management and investors in assessing the Company’s historical and future performance.




About Urologix


Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix’ Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Prostiva® RF Therapy System delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH symptoms. Both of these therapies provide safe, effective and lasting relief of the symptoms and obstruction due to BPH. Prostiva® is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix.


If you’d like more information on this topic, please contact Brian Smrdel at (763) 475-7696 or bsmrdel@urologix.com or to learn more about Urologix and its products and services, visit their website at www.urologix.com.


The Urologix, Inc. logo is available at www.urologix.com/clinicians/resource-library.php.


Forward Looking Statements


This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate” or “continue” or comparable terminology are intended to identify forward-looking statements. Such forward looking statements include, for example, the effectiveness of the Company’s sales and marketing strategies and organization, the Company’s future revenue and operating performance, or about the development and marketing of new products. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause the actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s Annual Report on Form 10-K for the year ended June 30, 2012 and other documents filed with the Securities and Exchange Commission.


Urologix Media Contact Urologix Investor Relations Contact
Karen Snay Brian Smrdel
(513) 484-2987 (763) 475-7696
KSnay@urologix.com Bsmrdel@urologix.com




Urologix, Inc.

Statements of Operations

(Unaudited, in thousands, except per share data)


   Three Months Ended
June 30,
   Twelve Months Ended
June 30,
   2013   2012   2013   2012 
Sales  $4,184   $4,497   $16,590   $17,027 
Cost of goods sold (1)    2,279    2,220    8,407    8,645 
Gross profit   1,905    2,277    8,183    8,382 
Costs and expenses:                    
Sales and marketing   2,080    2,113    7,719    7,027 
General and administrative   421    820    2,515    3,393 
Research and development   514    577    2,269    2,189 
Change in value of acquisition consideration   (79)   (172)   (447)   (172)
Gain on demutualization           (321)    
Medical device tax   65        106     
Amortization   26    26    104    90 
Impairment of identifiable intangible assets (1)   160        160     
Total costs and expenses   3,187    3,364    12,105    12,527 
Operating loss   (1,282)   (1,087)   (3,922)   (4,145)
Interest expense   (207)   (111)   (555)   (482)
Gain on debt extinguishment (2)   206        206     
Foreign currency exchange gain/(loss)   2    (10)   (7)   (13)
Loss before income taxes   (1,281)   (1,208)   (4,278)   (4,640)
Income tax expense/(benefit)   (34)   17    14    55 
Net loss  $(1,247)  $(1,225)  $(4,292)  $(4,695)
Net loss per common share--basic  $(0.06)  $(0.08)  $(0.21)  $(0.32)
Net loss per common share--diluted  $(0.06)  $(0.08)  $(0.21)  $(0.32)
Weighted average number of common shares outstanding--basic   20,909    14,797    20,703    14,741 
Weighted average number of common shares outstanding--diluted   20,909    14,797    20,703    14,741 


(1)Total impairment charge of $434,000 in the fourth quarter of fiscal year 2013 includes a $274,000 impairment charge to the developed technology intangible asset reported in cost of goods sold with the remaining $160,000 impairment charge reported in operating expense.
(2)The gain on extinguishment of debt is a result of the restructuring of $7.5 million in outstanding Prostiva liabilities into a $2.0 million cash payment and a $5.3 million note payable.




Urologix, Inc.

Balance Sheets

(Unaudited, in thousands)


   June 30,
   June 30,
Current assets:          
Cash  $2,290   $1,899 
Accounts receivable, net   2,132    2,132 
Inventories   1,952    1,448 
Prepaids and other current assets   128    290 
Total current assets   6,502    5,769 
Property and equipment:          
Property and equipment   12,165    12,006 
Less accumulated depreciation   (11,430)   (11,144)
Property and equipment, net   735    862 
Other intangible assets, net   1,587    2,262 
Goodwill   3,036    3,115 
Long-term inventories   662    663 
Other assets   5    5 
Total assets  $12,527   $12,676 
Current liabilities:          
Accounts payable (1)  $628   $3,376 
Accrued compensation   721    732 
Deferred income   5    7 
Short-term deferred acquisition payment (1)   681    2,395 
Other accrued expenses   602    779 
Total current liabilities   2,637    7,289 
Deferred tax liability   36    35 
Long-term deferred acquisition payment   4,026    4,613 
Long-term debt (1)   5,333     
Other accrued liabilities   75    113 
Total liabilities   12,107    12,050 
Shareholders’ equity:          
Common stock   208    147 
Additional paid-in capital   119,230    115,205 
Accumulated deficit   (119,018)   (114,726)
Total shareholders’ equity   420    626 
Total liabilities and shareholders’ equity  $12,527   $12,676 


(1)The material change in this account from June 30, 2012 is a result of the restructuring of the Prostiva liabilities.



Urologix, Inc.

Condensed Statements of Cash Flows

(Unaudited, in thousands)


   Year Ended June 30, 
   2013   2012 
Operating Activities:          
Net loss  $(4,292)  $(4,695)
Adjustments to reconcile net loss to net cash used for operating activities:          
Depreciation and amortization   674    695 
Impairment of identifiable intangible assets   434     
Employee stock-based compensation expense   257    359 
Provision for bad debts   (23)   (34)
Loss on disposal of assets   7    15 
Accretion and interest expense on deferred acquisition payments   544    644 
Net adjustment to acquisition consideration   (447)   (172)
Gain on debt extinguishment   (206)    
Deferred income taxes   1    35 
Change in operating items, net of acquisition:          
Accounts receivable   23    (740)
Inventories   (626)   131 
Prepaids and other assets   162    (41)
Accounts payable   1,760    2,635 
Accrued expenses and deferred income   (227)   455 
Net cash used for operating activities   (1,959)   (713)
Investing Activities:          
Purchases of property and equipment   (79)   (57)
Acquisition of business   (1,368)   (500)
Purchases of intellectual property   (32)   (8)
Net cash used for investing activities   (1,479)   (565)
Financing Activities:          
Proceeds from stock option exercises   15    116 
Issuance of common stock   3,814     
Net cash provided by financing activities   3,829    116 
Net decrease in cash   391    (1,162)
Beginning of period   1,899    3,061 
End of period  $2,290   $1,899 


Supplemental cash-flow information

Income taxes paid during the period  $17   $12 
Net amount of inventory transferred to property and equipment  $202   $293 
Non-cash consideration for acquisition  $   $6,532 
Deferred acquisition payment and accounts payable transferred to long- term debt  $5,333   $ 



The following information was filed by Urologix Inc (ULGX) on Wednesday, August 21, 2013 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Urologix Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Urologix Inc.


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Get a Better Picture of a Company's Performance

Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years


Log in with your credentials


Forgot your details?

Create Account